The four members of the ERBB (HER) family of transmembrane receptor tyrosine kinases are frequently activated in cancer by several mechanisms such as mutation, amplification or autocrine ligand-receptor stimulation. We recently identified gene fusions involving the ERBB ligand gene, NRG1, which represent a novel mechanism for ERBB pathway deregulation.
Background

ERBB1 (EGFR) (1), ERBB2 (HER2)
, ERBB3 (3, 4) , and ERBB4 (5) constitute the ERBB family of transmembrane receptor tyrosine kinases (RTK). These RTKs are composed of a large extracellular ligand-binding domain, a transmembrane domain, a small intracellular juxtamembrane domain, a kinase domain, and a C-terminal tail (6) . Upon ligand binding, these receptors form hetero-or homodimers, which induce the phosphorylation of their intrinsic kinase domain, resulting in the activation of the downstream PI3K-AKT and MAPK pathways (7) (8) (9) . There are 13 polypeptide extracellular ligands for these RTK, all of them carrying an EGF-like consensus sequence, consisting of six cysteine residues. These ligands can be subdivided in those that specifically bind EGFR and ERBB4 (such as EGF, TGF-a, amphiregulin, epiregulin, BTC, HB-EGF, and EPR), and the neuregulins (NRGs), which bind to ERBB3 (NRG1 and NRG4) and to ERBB4 (NRG1-NRG4) (10) . ERBB receptors are expressed in many cells of the epithelial, mesenchymal, and neuronal lineages, in which they have diverse roles in development, proliferation, and differentiation (11) . Aberrant tyrosine kinase activity of ERBB receptors owing to gene amplification and mutations (EGFR and ERBB2) (12, 13, 14) , or autocrine ligand-receptor stimulation (10) , can result in growth stimulation and tumorigenesis in various tumour types, including cancers of the breast, lung, brain, head and neck, and colon (12) .
Contrary to ERBB1 and ERBB4, ERBB2 and ERBB3 are non-autonomous receptors and therefore their activation relies on their hetero-dimerization with other ERBB receptors:
ERBB2 lacks the capacity to interact with growth factor ligands (15) but is the preferred dimerization partner of the other three receptors (16) . ERBB3 is generally considered to be kinase-deficient (17) although it has a low level of kinase activity (1000-fold less than EGFR) (18, 19) . Interestingly, the heterodimer ERBB2-ERBB3 is considered the most transforming and mitogenic one (20) (21) (22) , as suggested by the following: first, ERBB2-containing heterodimers undergo slow endocytosis, recycling more frequently back to the cell surface (23) (24) (25) . Similarly, upon ligand binding and hetero-dimerization, ERBB3 undergoes tyrosine phosphorylation and can recruit PI3K but not GRB2, enabling ERBB3 to evade ligand-induced degradation (23, 26) ; and second, ERBB2-ERBB3 leads to the activation of both the PI3K-AKT and the MAPK pathways, strongly enhancing cellular proliferation and evasion of apoptosis (20, 21) .
Since the main ligands for ERBB3 are neuregulins, these molecules also activate ERBB2-ERBB3 heterodimers. In fact, co-expression of ERBB2 and ERBB3 constitutes a highaffinity receptor for these ligands (27) . Neuregulins are signalling proteins mainly expressed in the nervous system, the heart, and the breast (28) . They comprise a large family of growth factors that induce dimerization and activation of ERBB receptors (29) . Neuregulins are encoded by four individual genes (NRG1-4), of which NRG1 is the best characterized. NRG1
generates six types of proteins (I-VI), and at least 31 isoforms (29) . All of these isoforms have an extracellular EGF-like domain that induces activation of ERBB receptor tyrosine kinases.
Contrary to most NRG1 isoforms that undergo proteolytic cleavage resulting in the release of the EGF-like domain, type III NRG1s have a membrane-tethered EGF-like domain that restricts the signalling to cell-cell interactions mainly, although a small amount of the EGF-like domain of these isoforms has been found secreted into the medium (30).
ERBB3 is not frequently affected by mutation or amplification in cancer (14) ; by contrast, overproduction of ligands is another mechanism by which cancers aberrantly activate ERBB receptors. Several examples point towards the existence of an autocrine loop between ERBB3 and NRG1: in ovarian tumours that overexpressed NRG1 and ERBB3, inactivation of ERBB3 suppressed cancer growth in laboratory models (31) . Similarly, an NRG1-mediated autocrine loop inducing ERBB3 activation was also discovered in head and neck cancer cells lacking ERBB2 amplification, and these cells were particularly sensitive to the EGFR/ERBB2 kinase inhibitor, lapatinib (32) . Finally, analyses of prostate cancer cells and tumours suggest the existence of a paracrine loop involving NRG1 and the ERBB2-ERBB3 heterodimer (33) .
We recently discovered recurrent CD74-NRG1 gene fusions, which result in the expression of the NRG1 III-β3 isoform in the otherwise NRG1-negative invasive mucinous subtype of lung adenocarcinomas (IMA) (34) . CD74-NRG1 activates ERBB3 as well as PI3K-AKT signalling (34) , thus promoting anchorage-independent growth of NIH-3T3 cells (35) ( Fig. 1) . Furthermore, NRG1 fusion-mediated signalling could be suppressed by clinically approved kinase inhibitors (35) . NRG1 fusions are preferentially found in women who had never smoked, and whose tumours are negative for other known mutant oncogenic gene mutations such as those in KRAS (frequently mutated in IMA), or EGFR (34, 35) . In another study, CD74-NRG1 positive tumours displayed uncommon radiological features in comparison to what it is usually seen in IMA (36) .
Clinical-Translational Advances
Invasive mucinous adenocarcinoma (IMA) accounts for 2-10% of all lung adenocarcinomas and is associated with an unfavourable clinical course because it usually presents as multifocal unresectable disease, for which no effective treatment exists (37) (38) (39) (40) . KRAS mutations were, until recently, the only recurrent oncogenic mutations identified in IMA, with a frequency ranging from 50% in Asians to 80% in Caucasians. NRG1 fusions are the first potentially treatable oncogenic driver alteration associated with a specific lung adenocarcinoma subtype and in contrary to KRAS mutations, which are associated with tobacco use, NRG1 fusions occur in KRAS-negative IMA of never smokers. Taking all together, the discovery of recurrent, oncogenic and possibly targetable NRG1 fusions may represent a therapeutic opportunity for these tumours (34, 35) .
Since NRG1 fusions act through activation of ERBB2-ERBB3 heterodimers (34) , blocking the activity of these receptors may be the best strategy to treat NRG1-rearranged tumours. Similar to EGFR and ERBB4, the extracellular domain of ERBB3 probably exists in Research. on (41) . By contrast, the crystal structure of ERBB2 reveals a constitutively activated conformation similar to that of ligand-bound EGFR. Although more mechanistic details exist for ERBB2 than for ERBB3 (14) , and therefore more drugs are available for the former, blocking only this receptor might not be enough to completely shut down the signalling elicited by ERBB2-ERBB3. In fact, the effect of single agent lapatinib or afatinib (irreversible small-molecule inhibitor of the ERBB2 and EGFR tyrosine kinases (42)) has already been tested for NRG1 fusions in vitro, and downstream signalling was not completely shut down, although an inhibitory effect was observed (35) . Reactivation of ERBB3 has been observed as a resistance mechanism to EGFR and ERBB2 inhibitors (31, (43) (44) (45) (46) (47) (48) (49) , and such mechanism might help NRG1-rearranged tumour cells escape exclusive targeting of ERBB2. A more successful approach could be to block ERBB2-ERBB3 hetero-dimerization. In this context, ligand-induced ERBB2-ERBB3-PI3K complexes can be disrupted by pertuzumab (monoclonal antibody that recognizes an epitope in the hetero-dimerization domain II of ERBB2 (50)), whereas ligand-independent complexes might be dissociated by trastuzumab (51). However, it is important to note that the observed clinical efficacy of all therapeutic inhibitors against ERBB2 has been limited to breast cancer with overexpression of this gene (14) . 
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